RecruitingNeurodegenerative DiseasesLeukodystrophyAtaxia
Home Exercise for Individuals With Neurodegenerative Disease
Eligible age
5–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary goal of this study is to address the need for targeted therapeutic interventions for impairments that impact walking in related neurodegenerative diseases.
Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
You may qualify if…
- ✓ The eligibility criteria for males is X-linked adrenoleukodystrophy as determined by biochemical determination or genetic testing.
- ✓ The eligibility criteria for females is X-linked adrenoleukodystrophy as determined by biochemical determination, genetic testing, or pedigree analysis.
- ✓ The Leukoenceophalopathy with brainstem and spinal cord involvement and lactate elevation inclusion criterion is a confirmed DARS2 mutation through genetic analysis.
- ✓ For people with cerebellar ataxia, people with diagnoses of cerebellar damage from stroke, tumor or degeneration will be included. Those with a genetically confirmed cerebellar disorder will be asked to provide their genetic testing to note their particular type of ataxia.
- ✓ We will also include patients with other neurodegenerative diseases similar to these disorders as determined by chart review and clinical exam.
- ✓ Healthy Volunteers
- ✓ Able to stand for 30 seconds without upper extremity support
- ✓ Ambulatory (including use of a cane or a walker)
You may not qualify if…
- ✕ Other medical or psychological conditions which in the clinical judgement of the investigator would interfere with acquiring the study information or performing the exercises safely including but not limited to:
- ✕ Uncontrolled hypertension, orthopedic conditions, diabetes, seizure disorder, peripheral vestibular loss, severe aphasia, dementia, pregnancy
Where it's recruiting
Maryland
Baltimore
Source: ClinicalTrials.gov · NCT05443906 · last updated 2026-09-16